Baseline characteristics, comorbidities, and outcomes of COVID-19 patients hospitalized in Southwest Georgia, U.S. – an interim analysis of an early hot spot

1) University of Georgia College of Pharmacy, Albany, GA, 2) John D. Archbold Memorial Hospital, Thomasville, GA, 3) University of Colorado, Anschutz Medical Campus, Aurora, CO, 4) Hospital Infantil de México, Federico Gómez, México City, México, 5) University of Georgia College of Pharmacy, Athens, GA

Background

Understanding the spectrum of disease severity is critical for identifying unrecognized risk factors associated with morbidity and mortality from COVID-19. The purpose of this study was to describe baseline characteristics, clinical presentation, and outcomes among patients hospitalized with COVID-19 in a major hotspot in the Southeastern U.S.

Objectives

The primary outcome was in-hospital mortality, which was assessed through discharge or June 14, 2020, whichever occurred first. Secondary outcomes included comorbidities, laboratory and radiographic findings, as well as clinical course.

Methods

This multicenter retrospective chart review included adult patients hospitalized with COVID-19, defined by laboratory-detected SARS-CoV-2 infection, in Southwest Georgia. Categorical and continuous variables were presented as number (percentage [%]) and median (interquartile range [IQR]), respectively. We used the Mann-Whitney U test, Chi-squared test, or Fisher's exact test to compare differences between survivors and non-survivors. Logistic regression was performed to investigate the relationship between baseline characteristics and clinical outcomes and the risk of in-hospital mortality among hospitalized COVID-19 patients.



UNIVERSITY OF GEORGIA

Daniel B. Chastain¹, Sharmon P. Osae¹, Ashley M. Burt², Kevin VanLandingham², Natalie Sibold¹, Andrés F. Henao-Martínez³, Carlos Franco-Paredes^{3,4}, Henry N. Young⁵

			Results				
Table 1. Baseline characteristics of hospitalized COVID-19 patients					Table 2. Logistic regression analysis of in-hospital		
Characteristic	Total cohort (n=120)	Survivor (n=96)	Non-survivor (n=24)	P value	mortality risk factors for hospitalized COVID-19 patients		
Age (years), median (IQR)	61 (50-72)	60 (48.8-69)	71.5 (60.5-78.3	0.032	Variables	OR (95% CI)	P value
Male gender	53 (44)	41 (43)	12 (50)	0 5 2 0	Age	1 (0.9-1.1)	0.136
Female gender	67 (56)	55 (57)	12 (50)	- 0.320	Sex	0.8 (0.3-2.0)	0.576
Race					Caucasian	2.5 (0.8-8.4)	0.126
 African American 	87 (73)	74 (77)	13 (54)		Latinx	2.8 (0.4-18.5)	0.298
 Caucasian 	30 (25)	19 (20)	11 (46)	0.025	Hypertension	1 (0.4-2.6)	1
Latinx	3 (3)	3 (3)	0 (0)				
BMI (kg/m ²), median (IQR)	32.8 (26.2-39.5)	33.4 (27.9-39.4)	29.7 (23.1-42.1) 0.494	Diabetes mellitus without	0.9 (0.3-2.9)	0.941
Pre-existing comorbidities	106 (88)	82 (85)	24 (100)	0.047	complications		
 Hypertension 	80 (76)	64 (78)	16 (67)	1	Diabetes mellitus with	2.0 (0.7-6.1)	0.208
 Diabetes mellitus without 	35 (33)	29 (35)	6 (25)	0.616	end organ damage		
complications					Dementia	3.1 (0.7-13.8)	0.135
 Diabetes mellitus with end organ damage 	23 (22)	16 (20)	7 (29)	0.164	Moderate to severe renal	3.3 (1.0-10.8)	0.045
Dementia	11 (10)	5 (6)	6 (25)	0.003	UISEASE		
 Moderate to severe renal disease 	22 (21)	14 (17)	8 (33)	0.034	Mechanical ventilation	2.7 (0.8-9.6)	0.127
Charlson comorbidity index, median	4 (2-6)	3 (1-5)	5.5 (3.75-7)	0.271	AKI	1.2 (0.4-3.67)	0.715
(IQR) Clinical symptoms prior to hospital ad	Imission				ARDS	3.1 (0.7-13.4)	0.128
 Shortness of breath 	83 (69)	67 (70)	16 (67)	0.767	Conclusions		
• Fever	75 (63)	61 (64)	14 (58)	0.637	Overall mortality was 20%, which was significantly		
 Cough 	63 (53)	55 (57)	8 (33)	0.036			
Figure 1. Clinical o	utcomes of hos	pitalized COVIC	0-19 patients	 Survivor Non-survivor 	with pre-existing comorb and renal disease. In ad	dities, specifically dition, mortality wa	dementia IS Oplicatio
100% 80%	p<0.001 80%	p=0.027 75%	p<0.001	p<0.001	regression, pre-existing moderate to severe renal disease was associated with increased odds of in- hospital mortality. Most reports of COVID-19 have focused on large urban settings. However, early during the pandemic, we identified a large cluster of cases with a high-case fatality rate in a semirural setting in Southwest Georgia		
60% p<0.001 40% p=0.011 30% 20% 8% 3% 3% 50% Transfer to ICLL Renal replacement	18%	36%	55% 10%				
therany	ventilation			00001000010	Setting in Southwest Ge	orgia.	





Disclosures: The use of REDCap[™] supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.

Address correspondence to: Daniel B. Chastain, Pharm.D. BCIDP, AAHIVP daniel.chastain@uga.edu